Prior to main analyses, data will be assessed for univariate and multivariate outliers, non-normality and missing data.
This implies for the evaluation study in the current project that: 1) the evaluation design is as rigorous as possible, 2) the implementation process is monitored by assessing process variables, 3) in the analyses it will be assessed how process variables influence intervention outcomes, and 4) (objective) organizational outcomes are measured.
The analyses described above will be assessed for all four clinical topics.
For primary analyses, treatment outcomes will be assessed by ANCOVA, with change in anxiety score as the baseline variable, while the baseline anxiety score and other baseline characteristics that significantly differ between groups will serve as covariates.
For primary analyses, treatment outcomes will be assessed by ANCOVA, with change in anxiety score as the baseline variable, while the baseline anxiety score and other baseline characteristics that significantly difference between groups will serve as covariates.
In the effect modification analyses, statistical significance will be assessed by multiplying the dummy variable for whichever intervention is being considered by the continuous/scale version of the potential modifier; the latter may then be categorized for communication purposes.
Program cost and cost-effectiveness analyses of the chlorhexidine coating will be assessed from patient and dental plan perspectives [ 30].
Beforehand, as preparation for the interviews, the supervision records will be analysed and the quantitative outcomes will be assessed at an individual level.
Variability of response to vitamin D supplementation will be assessed by analyses of prespecified participant subgroups defined by baseline variables (e.g., race, ethnicity, BMI, waist circumference, age, geographic location, calcium intake, 25OHD concentration).
